UA86528C2 - Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону - Google Patents
Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинонуInfo
- Publication number
- UA86528C2 UA86528C2 UAA200713931A UAA200713931A UA86528C2 UA 86528 C2 UA86528 C2 UA 86528C2 UA A200713931 A UAA200713931 A UA A200713931A UA A200713931 A UAA200713931 A UA A200713931A UA 86528 C2 UA86528 C2 UA 86528C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pyrazolopyrimidine derivative
- prevention
- treatment
- liver diseases
- present
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title abstract 5
- 208000019423 liver disease Diseases 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 2
- 208000007232 portal hypertension Diseases 0.000 abstract 2
- 210000003240 portal vein Anatomy 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Даний винахід стосується фармацевтичної композиції для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону, як активний інгредієнт. За даним винаходом похідна піразолопіримідинону має значний ефект на інгібування синтезу колагену в зірчастих клітинах печінки та діє безпосередньо на портальну вену. Зокрема, можна збільшити її діаметр та посилити потік крові портальної вени та, в результаті, знизити її тиск. Тому, похідну піразолопіримідинону можна застосовувати переважно для попередження та лікування фіброзу печінки, цирозу печінки, спричиненого фіброзом печінки, портальної гіпертензії та різних ускладнень, спричинених портальною гіпертензією. Крім того, похідна піразолопіримідинону за даним винаходом може знизити частоту дозування, тому що у неї довгий період напіввиведення, та тому, що вона має перевагу покращення режиму прийому лікарського засобу пацієнтами, що страждають на хронічні хвороби печінки.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050050033 | 2005-06-10 | ||
| PCT/KR2005/003526 WO2006132460A1 (en) | 2005-06-10 | 2005-10-21 | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA86528C2 true UA86528C2 (uk) | 2009-04-27 |
Family
ID=37498629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200713931A UA86528C2 (uk) | 2005-06-10 | 2005-10-21 | Засіб для попередження та лікування хвороб печінки, що містить похідну піразолопіримідинону |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8796286B2 (uk) |
| EP (1) | EP1888074B1 (uk) |
| JP (1) | JP4879977B2 (uk) |
| KR (1) | KR100914445B1 (uk) |
| CN (1) | CN101193636B (uk) |
| AT (1) | ATE537832T1 (uk) |
| AU (1) | AU2005332719B2 (uk) |
| BR (1) | BRPI0520209A2 (uk) |
| CA (1) | CA2611638C (uk) |
| CY (1) | CY1112637T1 (uk) |
| DK (1) | DK1888074T3 (uk) |
| ES (1) | ES2376628T3 (uk) |
| IL (1) | IL187678A (uk) |
| MX (1) | MX2007015365A (uk) |
| NO (1) | NO20076053L (uk) |
| NZ (1) | NZ564369A (uk) |
| PT (1) | PT1888074E (uk) |
| RU (1) | RU2369392C2 (uk) |
| UA (1) | UA86528C2 (uk) |
| WO (1) | WO2006132460A1 (uk) |
| ZA (1) | ZA200800180B (uk) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954295B2 (ja) * | 2006-12-28 | 2012-06-13 | インセクト バイオテック カンパニー， リミティッド | アラザイムを有効成分とする肝機能保護用薬学的組成物 |
| WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| WO2012009545A1 (en) * | 2010-07-14 | 2012-01-19 | Cumberland Emerging Technologies, Inc | Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists |
| EP2873017B1 (en) | 2012-07-11 | 2021-09-01 | University of Mississippi Medical Center | Method for the detection and staging of liver fibrosis from image acquired data |
| WO2015176060A1 (en) | 2014-05-16 | 2015-11-19 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
| US12161632B2 (en) | 2014-05-16 | 2024-12-10 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
| CN114569608A (zh) | 2015-06-30 | 2022-06-03 | 坎伯兰医药品股份有限公司 | Aerd/哮喘中的血栓烷受体拮抗剂 |
| US10064845B2 (en) | 2016-05-11 | 2018-09-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
| CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
| AU2020356193A1 (en) | 2019-09-24 | 2022-05-19 | Children's Hospital Of Philadelphia | Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions |
| CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
| WO2023018972A1 (en) * | 2021-08-13 | 2023-02-16 | Mezzion Pharma Co., Ltd. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19832429A1 (de) * | 1998-07-18 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| KR100353014B1 (ko) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
| US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| GB0202254D0 (en) | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| GB0214784D0 (en) | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
| WO2004037183A2 (en) | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
| WO2004108662A1 (ja) | 2003-05-15 | 2004-12-16 | Kumiai Chemical Industry Co., Ltd. | フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤 |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| CA2528975A1 (en) * | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
-
2005
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es not_active Expired - Lifetime
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en not_active Expired - Lifetime
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko not_active Expired - Lifetime
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en not_active Ceased
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
-
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
-
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
-
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101193636A (zh) | 2008-06-04 |
| CY1112637T1 (el) | 2016-02-10 |
| EP1888074B1 (en) | 2011-12-21 |
| ZA200800180B (en) | 2009-01-28 |
| CA2611638C (en) | 2010-08-24 |
| IL187678A0 (en) | 2008-11-03 |
| CN101193636B (zh) | 2011-12-28 |
| DK1888074T3 (da) | 2012-01-23 |
| RU2007149474A (ru) | 2009-07-20 |
| NO20076053L (no) | 2008-02-27 |
| ATE537832T1 (de) | 2012-01-15 |
| ES2376628T3 (es) | 2012-03-15 |
| IL187678A (en) | 2013-04-30 |
| EP1888074A1 (en) | 2008-02-20 |
| BRPI0520209A2 (pt) | 2009-04-22 |
| HK1119596A1 (en) | 2009-03-13 |
| JP2008543748A (ja) | 2008-12-04 |
| PT1888074E (pt) | 2012-03-01 |
| JP4879977B2 (ja) | 2012-02-22 |
| KR100914445B1 (ko) | 2009-08-28 |
| RU2369392C2 (ru) | 2009-10-10 |
| US8796286B2 (en) | 2014-08-05 |
| NZ564369A (en) | 2010-03-26 |
| AU2005332719B2 (en) | 2010-05-13 |
| EP1888074A4 (en) | 2010-06-23 |
| CA2611638A1 (en) | 2006-12-14 |
| AU2005332719A1 (en) | 2006-12-14 |
| US20080207646A1 (en) | 2008-08-28 |
| MX2007015365A (es) | 2008-02-12 |
| WO2006132460A1 (en) | 2006-12-14 |
| KR20060128605A (ko) | 2006-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200800180B (en) | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative | |
| AU2018253620A1 (en) | Injectable botulinum toxin formulations | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| EA200501570A1 (ru) | Новые гидроксаматы как лечебные средства | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| EA200501203A1 (ru) | Жидкие фармацевтические композиции палоносетрона | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
| WO2005094897A3 (en) | Pegylated ion channel modulating compounds | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| WO2009120885A3 (en) | Stabilizing lipid compositions for oral pharmaceutical agents | |
| WO2007056236A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously | |
| WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
| MY148300A (en) | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative | |
| SE0303135D0 (sv) | Controlled food effect composition | |
| WO2007009691A3 (en) | Combination of substituted pyrazolines and anti -addictive agent | |
| SE0203817D0 (sv) | New composition | |
| WO2004026319A3 (en) | Pharmaceutical compositions increasing camp useful for the treatment of cancers | |
| WO2008005806A3 (en) | Therapeutic methods, compositions, and compounds |